Fig. 2.

Identification of glioma-specific epigenetic liquid biopsy (GeLB) as a diagnostic marker for gliomas. (A) Schematic diagram of the method (supervised machine learning) and approach (discovery and independent validation) to identify the glioma-eLB CpG signatures used to generate the GeLB score (see Materials and Methods for details). (B) Principal component analysis. (C, D) Hierarchical clustering for (C) primary tumor tissue and (D) non-tumorous cell and tissue types. (E) Receiver operating characteristic curve derived from the independent validation set. (F) GeLB score calculated for each tumor tissue and available cfDNA methylation serum. (G) GeLB score distribution by glioma grade (II/III and IV). Abbreviation: cfDNA, cell-free DNA.